Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma

Journal of Immunotherapy

Volumn 28, Issue 6, 2005, Pages 535-541

  Wang, Yi ^a   Harada, Mamoru ^a,b   Yano, Hirohisa ^a,b   Ogasawara, Sachiko ^a,b   Takedatsu, Hiroko ^b   Arima, Yoshimi ^a   Matsueda, Satoko ^b   Yamada, Akira ^a,b   Itoh, Kyogo ^a,b  

^a KURUME UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenocarcinoma; Cytotoxic T lymphocytes; Immunotherapy; Peptide; Prostatic acid phosphatase

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; HLA A24 ANTIGEN; MESSENGER RNA; PROSTATE ANTIGEN;

ADENOCARCINOMA; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER TISSUE; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; WESTERN BLOTTING;

EID: 26444432150     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000175490.26937.22     Document Type: Article

References (25)

1. Gutman E, Sproul E, Gutman A. Significance of increased phosphatase activity of bone at the site of osteoblastic metastases secondary to carcinoma of the prostate gland. Am J Cancer. 1936;28:485-495.
2. Jacobs EL, Haskell CM. Clinical use of tumor markers in oncology. Curr Prob Cancer. 1991;15:299-360.
3. Dattoli M, Wallner K, True L, et al. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for higher risk prostate carcinoma: Influence of prostatic acid phosphatase. Cancer. 2003; 97:979-983.
4. Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A Phase 2 trial. Prostate. 2004;60: 197-204.
5. Lam KW, Li CY, Yam LT, et al. Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody. Prostate. 1989; 15:13-21.
6. Solin T, Kontturi M, Pohlmann R, et al. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): Evaluation by RNA blot analyses. Biochim Biophys Acta. 1990;1048:72-77.
7. Sobin LH, Hjermstad BM, Sesterhenn IA, et al. Prostatic acid phosphatase activity in carcinoid tumors. Cancer. 1986;58:136-138.
8. Kamoshida S, Tsutsumi Y. Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: Distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal grand. Hum Pathol. 1990;21:1108-1111.
9. Kimura N, Sasano N. Prostate-specific acid phosphatase in carcinoid tumors. Virchows Arch A Pathol Anat Histopathol. 1986;410:247-251.
10. Yam LT, Janckila AJ, Li CY, et al. Presence of "prostatic" acid phosphatase in human neutrophils. Invest Urol. 1981;19:34-38.
11. Tepper SL, Jagirdar J, Heath D, et al. Homology between the female paraurethral (Skene's) glands and the prostate. Immunohistochemical demonstration. Arch Pathol Lab Med. 1984;108:423-425.
12. Nowels K, Kent E, Rinsho K, et al. Prostate specific antigen and acid phophatase-reactive cells in cystitis cystica and glandularis. Arch Pathol Lab Med. 1988;112:734-737.
13. Kaneko Y, Motoi N, Matsui A, et al. Neuroendocrine tumors of the liver and pancreas associated with elevated serum prostatic acid phosphatase. Intern Med. 1995;34:886-891.
14. Jobsis AC, De Vries GP, Meijer AE, et al. The immunohistochemical detection of prostatic acid phosphatase: Its possibilities and limitations in tumor histochemistry. Histochem J. 1981;13:961-973.
15. Choe BK, Pontes EJ, Rose NR, et al. Expression of human prostatic acid phosphatase in a pancreatic islet cell carcinoma. Invest Urol. 1978;15: 312-318.
16. Epstein JI, Kuhajda FP, Lieberman PH. Prostate-specific acid phosphatase immunoreactivity in adenocarcinomas of the urinary bladder. Hum Pathol. 1986;17:939-942.
17. Seki K, Miyakoshi S, Lee GH, et al. Prostatic acid phosphatase is a possible tumor marker for intravascular large B-cell lymphoma. Am J Surg Pathol. 2004;28:1384-1388.
18. Inoue Y, Takaue Y, Takei M, et al. Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide. J Urol. 2001;166:1508-1513.
19. Robbins PF, Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol. 1996;8:628-636.
20. Renkvist N, Castelli C, Robbins PF, et al. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother. 2001;50:3-15.
21. Harada M, Noguchi M, Itoh K. Target molecules in specific immunotherapy against prostate cancer. Int J Clin Oncol. 2003;8:193-199.
22. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894-3903.
23. Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000;6:2175-2182.
24. Peshwa MV, Shi JD, Ruegg C, et al. Induction of prostate tumor specific CD8+ cytotoxic T lymphocytes in vitro using antigen presenting cells pulsed with prostatic acid phosphatase peptide. Prostate. 1998;36: 129-138.
25. Noguchi M, Itoh K, Yao A, et al. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24(+) HRPC patients. Prostate. 2005;63:1-12.